Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Gastrointestinal motility and autonomic nerve dysfunction].

M Hongo1, H Kawakami

  • 1Third Department of Internal Medicine, Tohoku University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|April 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A prospective, multicenter, observational study of trastuzumab deruxtecan in elderly patients with HER2-positive gastric cancer: EN-COURAGE.

ESMO gastrointestinal oncology·2026
Same author

Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study.

ESMO gastrointestinal oncology·2026
Same author

Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes in <i>BRAF</i> V600E-mutated metastatic colorectal cancer: GI-SCREEN <i>post-hoc</i> analysis.

ESMO gastrointestinal oncology·2026
Same author

WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD).

ESMO gastrointestinal oncology·2026
Same author

Real-world evaluation of interstitial lung disease/pneumonitis in patients treated with trastuzumab deruxtecan for HER2-positive advanced or recurrent gastric cancer: a postmarketing surveillance study in Japan.

ESMO open·2025
Same author

Computer-assisted surgery with markerless augmented reality for the surgical removal of mandibular odontogenic cysts: report of two clinical cases.

International journal of oral and maxillofacial surgery·2024
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Gastrointestinal motility relies on the autonomic and enteric nervous systems. Dysfunction in these systems, seen in conditions like diabetes or functional disorders, leads to various motility issues throughout the digestive tract.

Area of Science:

  • Neurogastroenterology
  • Autonomic Nervous System (ANS) research
  • Enteric Nervous System (ENS) research

Context:

  • Gastrointestinal (GI) motility is regulated by complex neural networks.
  • Autonomic Nervous System (ANS) and Enteric Nervous System (ENS) play crucial roles in GI function.
  • Dysregulation of these systems underlies numerous GI motility disorders.

Purpose:

  • To elucidate the impact of ANS and ENS dysfunction on gastrointestinal motility.
  • To connect generalized and localized nervous system disorders to specific GI motility problems.
  • To explore the role of ANS dysfunction in functional GI disorders.

Summary:

  • Autonomic Nervous System (ANS) and Enteric Nervous System (ENS) dysfunction significantly alter gastrointestinal motility.

Related Experiment Videos

  • Generalized autonomic dysfunction, common in diabetes, impairs esophageal peristalsis, gastric electrical activity, gastric emptying, and intestinal transit.
  • Localized ENS disorders cause conditions like achalasia and Hirschsprung's disease.
  • Functional GI disorders, including non-cardiac chest pain, non-ulcer dyspepsia, and irritable bowel syndrome, can stem from abnormal ANS function.

    • Impact:

    • Highlights the critical role of the ANS and ENS in maintaining normal GI function.
    • Provides insights into the pathophysiology of diverse GI motility disorders, from organic diseases to functional conditions.
    • Emphasizes the need for considering neurological factors in the diagnosis and management of GI motility disturbances.